Kitada M, Sawaragi I
Dept. of Obstetrics and Gynecology, Kansai Medical University.
Gan To Kagaku Ryoho. 1996 Jan;23(1):87-91.
We, in the Department of Obstetrics and Gynecology, Kansai Medical College, conducted an evaluation of the usefulness and safety of granisetron hydrochloride used for nausea and vomiting due to chemotherapy in patients with gynecological malignant tumors, with an additional study of the efficacy of different regimens. The subjects were 9 patients in whom 16 courses of CAP therapy were given (group A) and 13 patients in whom 24 courses of CAP therapy were given (group B). Granisetron hydrochloride 3 mg/body was administered by intravenous drip in the two groups before chemotherapy. Clinical symptoms of nausea, vomiting, and anorexia were observed for 2 days after anticancer drugs were administered in order to evaluate its efficacy. The percentage of patients who responded as "effective" or better was 90.0%. In different regimens, the efficacy was 93.8% in group A and 87.5% in group B. These results indicated clinically high usefulness in both groups. No side effects related to granisetron hydrochloride were found in this study.
我们在关西医科大学妇产科，对盐酸格拉司琼用于妇科恶性肿瘤患者化疗所致恶心和呕吐的有效性及安全性进行了评估，并额外研究了不同方案的疗效。研究对象为接受16个疗程CAP治疗的9例患者（A组）和接受24个疗程CAP治疗的13例患者（B组）。两组在化疗前均静脉滴注3mg/体的盐酸格拉司琼。在给予抗癌药物后观察2天恶心、呕吐和厌食的临床症状，以评估其疗效。反应为“有效”或更好的患者百分比为90.0%。在不同方案中，A组疗效为93.8%，B组为87.5%。这些结果表明两组在临床上均具有较高的有效性。本研究未发现与盐酸格拉司琼相关的副作用。
